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ABSTRACT 
 
Introduction: Chronic Obstructive Pulmonary Disease (COPD) is characterized by 
largely irreversible airflow limitation and is associated with several extra-pulmonary 
manifestations and comorbidities. Cardiovascular diseases are among the most 
frequent comorbid conditions affecting patients with COPD and have important 
prognostic implications for hospitalisation and mortality. 
In turn, COPD shares common risk factors with several cardiovascular diseases (i.e. 
smoking habit), while several features of COPD can predispose to cardiovascular 
disease (i.e. gas exchange abnormalities, polycythemia, systemic inflammation and 
sedentary lifestyle). Cardiovascular comorbidities in patients with COPD are under-
recognised and undertreated and should be actively sought and treated according to 
usual guidelines. 
 
Areas covered: This review will discuss the increased prevalence and prognostic 
implications of cardiovascular comorbidities in patients with COPD. The effect of 
COPD on the outcomes in cardiovascular disease will also be highlighted. The 
pathogenic mechanisms that underlie cardiovascular comorbidities in patients with 
COPD will also be reviewed. Finally, options for the management of cardiovascular 
comorbidities in patients with COPD will be discussed. 
 
Word count: 162 
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KEY ISSUES SECTION 
 
 Cardiovascular comorbidities are highly prevalent in patients with COPD 
 COPD is a well-known risk factor for the development of cardiovascular 
disease 
 Cardiovascular complications are a major contributor to morbidity and 
mortality in COPD 
 COPD has negative prognostic implications in patients with cardiovascular 
disease 
 Cardiovascular comorbidities are under-diagnosed in patients with COPD 
 COPD and cardiovascular disease share common risk factors 
 Several features of COPD are associated with increased cardiovascular risk 
 Cardiovascular comorbidities should be actively sought and treated in COPD 
according to usual guidelines 
 Management of COPD should be moving from a reductionist approach to an 
integrated approach to define, identify, and treat the multiple organ 
involvement of this complex syndrome 
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Introduction 
 
Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow 
limitation that is usually progressive and is associated with an abnormal inflammatory 
response in the lungs to noxious particles or gases1. The natural course of COPD is 
complicated by the development of extra-pulmonary manifestations and comorbidities 
that have important prognostic implications for hospitalisation and mortality2. 
Cardiovascular comorbidities are among the most frequent comorbid conditions 
affecting patients with COPD3,4. COPD is a well-known risk factor for the development 
of atherosclerosis and consequent cardiovascular complications5*, 6.  
The expiratory volume in the first second of a forced expiratory manoeuvre (FEV1) is 
also known to be an independent predictor of cardiovascular complications in COPD7. 
Even a moderate reduction in FEV1 increase the risk of morbidity and death and relate 
to cardiovascular events by two to three times8-11. 
Coronary artery disease is common12* and undertreated in patients with COPD13. 
Heart failure (HF) is also very prevalent in patients with COPD14. Patients with COPD 
have also increased risk for cardiovascular arrhythmias15. Atrial fibrillation (AF) is more 
frequent in patients with COPD following coronary artery bypass grafting than in the 
general population16. 
Cardiovascular disease is a major contributor to both morbidity and mortality in 
patients with COPD7, 17-20. The presence of HF is associated with increased mortality 
in COPD21 and AF is an independent predictor of increased mortality and poor Health 
Related Quality of Life (HRQoL) in COPD patients, in comparison to the general 
population22. 
The presence COPD also has a negative effect on outcomes in patients with 
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cardiovascular disease. For example, cardiovascular events such as MI have worse 
outcome in patients with COPD in comparison to those without COPD9, 13. Several 
features of COPD have been thought to explain, at least in part, the increased 
prevalence of cardiovascular comorbidities (Table 1). 
This review will describe the prevalence of cardiovascular comorbidities and the 
prognostic implications in patients with COPD. The mechanisms linking cardiovascular 
disease and COPD will be also reviewed and the options for the management of 
cardiovascular comorbidities in patients with COPD will be discussed. 
 
Prevalence of cardiovascular comorbidities in COPD 
 
COPD is an independent risk factor for cardiovascular disease. Coronary artery 
disease (CAD) is very prevalent in COPD patients23. Analysis of a population-based 
cohort showed a higher prevalence of hypertension, diabetes mellitus and 
cardiovascular disease in individuals with airflow limitation of GOLD stage 3 and 424*. 
In the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints 
(ECLIPSE) cohort, Miller et al demonstrated an increased prevalence of 
cardiovascular comorbidities; including hypertension, angina, AMI, stroke, heart failure 
and arrhythmias; in patients with COPD in comparison to smokers and non-smokers 
with normal lung function25*. Interestingly, these associations were independent of the 
degree of airflow limitation. Moreover, in a population of patients with COPD with no 
symptoms or signs of cardiovascular disease, Iwamoto et al showed increased carotid 
intimal thickening, as a measure of subclinical atherosclerosis, when compared to 
smokers and non-smokers without airflow limitation12* (Figure 1). 
The lung health study, in 1,916 mild to moderate patients with COPD, showed a 
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significant relationship between airflow limitation and incidence of cardiovascular 
comorbidities7. In addition, the National Health Interview Survey, including 18,342 
subjects older than 40 years, showed that the presence of COPD increased the odds 
of cardiovascular disease by 2.726. 
COPD is a well-known risk factor for the development of atherosclerosis and 
cardiovascular complications4, 27-29 and is associated with increased arterial stiffness, 
a good predictor of vascular disease, independently of cigarette smoke exposure.  
Systemic arterial stiffness is increased in COPD patients compared to non-smokers 
and smokers with normal lung function, even after correction for smoking history30. In 
fact, arterial wall stiffness is associated with emphysema independently of other 
factors such as smoking history. This suggests that COPD constitutes an independent 
risk for CAD31**. The same is true for airflow limitation since the FEV1 is an independent 
predictor of death from myocardial infarction2. 
A large population-based study using the Atherosclerosis Risk in Communities (ARIC) 
cohort with 14 years follow up showed a crude increase in prevalence of 
cardiovascular events in individuals with COPD in comparison to controls32.  
Interestingly, the relative risks were markedly reduced after adjusting for covariates 
that included traditional cardiovascular risk factors, in contrast to the majority of work 
that has examined increased cardiovascular risk in COPD. These results suggest that 
this co-morbid condition may be mediated by the high prevalence of traditional risk 
factors in COPD. Indeed, both assumptions are supported by the literature. COPD and 
cardiovascular disease share common risk factors, such as smoking, that can 
contribute to the development of both conditions. Also, an enhanced inflammatory 
response in the lungs and systemically that occurs in COPD could contribute to the 
development of CVD in COPD patients33. 
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Heart failure is common in COPD and COPD is common in heart failure.  However, 
the association of COPD with left ventricular dysfunction is less well documented. By 
contrast, there is evidence that a reduction in the size of all four cardiac chambers 
occurs with increasing airflow limitation34. Emphysema is associated with impaired 
ventricular filling, reduce stroke volume and, consequently, a lower cardiac output35. 
This relationship of emphysema with cardiac function likely involves increased 
pulmonary vascular resistance and pulmonary hyperinflation36. Static hyperinflation 
showed a stronger association with cardiac chamber size than airflow limitation or the 
diffusion capacity for carbon monoxide 34. 
One study37 showed a prevalence of 20% for left ventricular dysfunction among COPD 
patients. In turn, heart failure appears to be under-diagnosed in patients with COPD14. 
  
Pulmonary arterial hypertension (PAH) is another cardiovascular manifestation in 
patients with COPD. Pulmonary hypertension has been associated with worse 
prognosis in COPD. The presence of pulmonary arterial hypertension in COPD 
constitutes a significant risk factor for acute exacerbation and hospitalization, and is 
associated with a worse survival54, 55. 
Approximately 50% of severe and very severe COPD patients have PAH38 . Patients 
with mild disease do not commonly have PAH at rest but may develop PAH during 
exercise. Right ventricular hypertrophy, dilation and dysfunction is linked to worse 
outcome in COPD39, 40 and can be present even with a slight increase in mean 
pulmonary arterial pressure41. A Spanish study assessing cardiovascular function after 
a first hospital admission for COPD identified that 64% of patients have cardiovascular 
dysfunction, 27% left- and 48% right-heart disorders, as assessed by heart ultrasound. 
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Pulmonary hypertension is usually mild in patients with COPD. In 1 to 3% of COPD 
patients, however, in whom pulmonary arterial pressure is very high (> 50mmHg)  and 
is out of proportion to the severity of the airflow limitation, it behaves like idiopathic  
PAH42. 
 
Prognostic implications of cardiovascular comorbidities in COPD 
 
The presence of cardiovascular comorbidities increases the risk of death in patients 
with COPD. Miller et al study on the ECLIPSE cohort showed that the survival 
probability was significantly reduced in those patients with cardiovascular 
comorbidities25* (Figure 2). Systemic arterial stiffness, an independent marker of 
cardiovascular risk43, 44** that is increased in COPD patients30, is associated with 
cardiovascular mortality45**. Moreover, for every 10% decrease in FEV1, 
cardiovascular mortality increases by approximately 28% and non-fatal coronary 
events increase by approximately 20% in mild to moderate COPD7.  
 
Hypertension, the most frequent cardiovascular comorbidity in COPD, also has 
implications for prognosis46.  
 
A study by Boudestein et al in a cohort of 405 patients with COPD showed that the 
presence of newly diagnosed heart failure significantly increased all-cause mortality 
independently of gender, age, history of ischaemic heart disease (IHD), hypertension, 
diabetes, atrial fibrillation, smoking history, and cardiovascular drug use47. 
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While patients with myocardial dysfunction and co-morbid COPD have an increased 
mortality, impaired cardiac function can also contribute to reduced physical activity in 
COPD48 which, in turn, is an independent prognostic factor for hospitalisations and 
mortality49. 
Left ventricular function assessed by echocardiography and N-terminal pro b-type 
natriuretic peptide (NT-pro-BNP - a biomarker of left ventricular strain) has a negative 
independent association with physical activity levels, after adjustment for GOLD stage 
or BODE score. A further study demonstrated an increase in NT-pro-BNP during 
ECOPD compared to recovery, and in particular in individuals who required admission 
to the intensive care unit50.  
A recent study of 186 consecutive patients with left ventricular systolic dysfunction in 
a heart failure clinic found that 39% had COPD diagnosed on spirometry, and those 
patients with heart failure and severe COPD had a worse prognosis than those with 
mild to moderate disease or normal lung function21. This higher mortality was again 
reported in patients with COPD compared to individuals without lung disease in a study 
of 800 patients hospitalized with cardiac failure51. 
 
There is an increased risk of death from myocardial infarction in COPD that is 
independent of age, sex and smoking history23. In a cohort of 14,703 patients with AMI 
from the Acute Myocardial Infarction Trial (VALIANT) study in which 8.6% subjects 
had COPD, all-cause mortality was increased in the COPD population (30%) in 
comparison to those patients without COPD (19%), a hazard ratio 1.14 (95% CI 1.02-
1.28)52.  
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In the ECLIPSE COPD cohort the presence of coronary artery calcification (CAC) on 
CT scan, a measure of atherosclerotic burden, was significantly higher in the COPD 
population than matched control subjects and was related to  mortality53**.  
 
Pathogenesis of the cardiovascular comorbidities 
COPD shares common risk factors with CAD such as cigarette smoking and older age. 
Cigarette smoking is the most important established risk factor for COPD and 
constitutes a major risk factor for other comorbidities.  
The effects of smoking are possibly related to the following comorbidities or extra-
pulmonary manifestations of COPD: heart failure, arrhythmias, hypertension, 
peripheral and coronary artery diseases, pulmonary vascular abnormalities, diabetes, 
osteoporosis, cancer, psychiatric disorders, muscle dysfunction/wasting, and 
infections54. 
Possible mechanisms relating cigarette smoking with cardiovascular comorbidities 
include increased systemic inflammation and oxidative stress, altered nitric oxide (NO) 
bioavailability and endothelial dysfunction55-57. However, the presence of COPD itself 
can constitute an increased risk for cardiovascular disease. In patients with COPD 
admitted due to an acute exacerbation, 8.3% had chest pain and/or serial ECG 
changes, fulfilling the 2007 universal definition of myocardial infarction58. Several 
features of COPD can be associated with increased cardiovascular risks, namely gas 
exchange abnormalities, polycythemia, systemic inflammation, lung hyperinflation and 
a sedentary lifestyle. Figure 3 illustrates the interaction of the different pathogenic 
mechanisms leading to cardiovascular disease in association with COPD discussed 
below. 
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Systemic Inflammation 
 
Systemic inflammation has been implicated in the pathogenesis of cardiovascular 
disease and endothelial dysfunction and the genesis of atherosclerotic plaques 59*. In 
turn, several studies and a meta-analysis have shown that a proportion of clinically 
stable patients with COPD have evidence of persistent systemic inflammation60. 
Systemic inflammation, either as increased circulating cytokines, chemokines and acute 
phase proteins, or as abnormalities in circulating cells, has been shown in COPD 
patients, particularly when the disease is severe or during exacerbations60, 61. Moreover, 
platelet-monocyte aggregates increased during exacerbations of COPD62. Platelet 
activation may represent one mechanism by which inflammation may enhance 
cardiovascular risk in COPD. 
Systemic inflammation in COPD is associated with an accelerated decline in lung 
function63. Elevated levels of circulating c-reactive protein (CRP), a marker of systemic 
inflammation, have been related to a reduced exercise tolerance and health related 
quality of life64 and with increased risk of hospitalizations and mortality65.  
Several origins have been proposed for the systemic inflammation in COPD patients, 
namely an effect of smoking, “spill-over” from lung inflammation, skeletal muscle, 
hyperinflation and bone marrow as sources of systemic inflammation, and the effect 
of tissue hypoxia. There is direct evidence that protein movement occurs from the lung 
to lymph and blood. Experimental data indicate that alveolar macrophages and 
bronchial epithelial cells are critically important in processing inhaled noxious gases 
and particles, and that the mediators they produce are also identified in the systemic 
response in COPD4. Moreover, systemic inflammation is a recognized risk factor for a 
number of medical conditions that are associated with COPD. Thus, COPD and some 
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of the extra-pulmonary manifestations and comorbidities share the same risk factors. 
On the other hand, COPD may trigger inflammation, inducing a cause-effect 
relationship between COPD and some of its extra-pulmonary manifestations. 
Systemic inflammation is now a recognised feature of COPD. Higher plasma 
fibrinogen during the stable phase has now been shown to independently predict 
exacerbation frequency66. However, in a study of subjects with moderate to severe 
COPD, CRP was not associated with survival, unlike airflow limitation and the BODE 
index67. 
A further analysis of the Lung Health Study investigated whether an imbalance of lung 
injury and repair (measured using serum highly sensitive CRP [hsCRP] and fibronectin 
respectively) could contribute to mortality68. In this large study of individuals with mild 
to moderate COPD followed for up to fifteen years, the ratio of fibronectin to hsCRP 
was significantly associated with all-cause mortality. A cross-sectional study of 2,553 
patients with airflow limitation from the Framingham cohort showed further 
relationships between systemic inflammatory markers and severity of COPD69. There 
were negative associations between FEV1 and CRP and IL-6, as well as p-selectin 
and ICAM, markers of endothelial function and predictors of cardiovascular risk. 
Inflammation is integrally involved in the initiation and progression of chronic diseases 
such as CVD70-72. Therefore, systemic inflammation, a feature of COPD, may be a link 
between COPD and the increased risk of cardiovascular disease in these patients. 
However, the association between systemic inflammation and poor outcome should 
be interpreted cautiously. Descriptive studies show associations but do not prove 
causality. Moreover, the inflammatory response is complex and most of the studies 
only report a limited panel of biomarkers 
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Vessel wall abnormalities and endothelial dysfunction 
 
Arterial stiffness is associated with increased emphysema, FEV1 per cent predicted 
and systemic inflammation31**. A large case-control study confirmed previous findings 
of an increase in systemic arterial stiffness in COPD in comparison with age and sex 
matched controls73. Arterial stiffness can be assessed using carotid-femoral pulse-
wave velocity (PWV), a measure that is predictive of cardiovascular events in healthy 
individuals and in patients with ischaemic heart disease. Increased arterial stiffness is 
associated with decreased coronary perfusion74**. Emphysema is thought to result 
from elastin degradation in the alveolar walls75. Recent evidence also suggests that 
increased arterial stiffness may also result from systemic elastin degradation in the 
arterial walls76**. Thus, lung and systemic elastin degradation may represent the 
mechanistic link between COPD and the increased risk of cardiovascular disease 
associated with this condition30. 
 
Endothelium function is usually assessed as the flow mediated dilation after reactive 
hyperaemia77. Early studies established that attenuated vascular responses occur 
prior to the development of atherosclerosis in response to a milieu of risk factors, thus 
making measurements attractive as a screening tool for cardiovascular risk78. A 
mechanistic study reported impaired brachial artery vasodilatation in patients with 
stable COPD in comparison with healthy smokers and non-smokers79.  
There has been further work examining the potential mechanisms of the increased 
cardiovascular morbidity and mortality associated with COPD, particularly related to 
abnormal systemic vascular function. However, some79, 80, but not all30, studies have 
demonstrated abnormal endothelial function in COPD patients in comparison with 
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smokers who have not developed COPD.  
There seem to be, therefore, more evidence supporting the role of arterial stiffness in 
the development of cardiovascular disease in COPD than endothelial dysfunction for 
which the evidence is more controversial.  
 
Accelerated Ageing 
 
Ageing is among the greatest known risk factor for most chronic diseases81. Around 
100,000 people worldwide die each day of age-related causes82. 
The number of changes in the body that occur with age is remarkably long and include 
changes in appearance, such as wrinkled skin, gradual reduction in height and weight 
loss due to loss of muscle and bone mass, decline in sexual activity (and menopause 
in women), and decline in the function of most organs such as renal, pulmonary, cardiac 
and cerebral function. 
Similarities between features of COPD and the ageing lung suggest that COPD may 
be a condition related to accelerated ageing83*. A simple example of this is the 
association between emphysema and facial wrinkling84. Animal models of premature 
ageing show structural changes in the lungs and skeletal muscle that resemble those 
in COPD85.  
Lung function declines with ageing. An accelerated rate of lung function decline is a key 
feature of COPD86. It has been proposed that a decline in organ function (such as the 
lung) is a feature of ageing in response to the accumulation of molecular and cellular 
damage until the balance between cell death and cell replication (regeneration) is 
affected by the “intrinsic biological clock” that regulates the number of cell divisions. 
Therefore, any noxious exposure that increases cellular damage has the potential to 
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accelerate the process of ageing in a particular organ. Thus, noxious inhalants, such as 
cigarette smoke, accelerate these age-related events in the lung due to modification of 
proteins, reduction in anti-ageing molecules and/or stimulation of pro-ageing 
molecules87. 
Ageing itself is associated with chronic degenerative disorders and when compared to 
healthy controls, telomere length, a marker of cellular ageing, is reduced in smokers 
with normal lung function88 and reduced further in COPD patients89, particularly in 
patients with emphysema90. These events may enhance lung inflammation79, since 
telomere shortening leads to cellular senescence and as a consequence enhanced 
inflammation in the lungs91. 
Exposure of human epithelial cells to cigarette smoke result in cell senescence as 
shown by an increase in the senescent markers, senescence associated β-
galactosidase (SA-B-gal) and p21 protein92. Increased markers of cell senescence have 
been found in Type II epithelial cells and fibroblasts from emphysematous lungs93, 94 
that would contribute to the pathogenesis of COPD. 
With increasing age the prevalence of cardiovascular disease increases by several 
times, and is the leading cause of death in people aged above 65 years and older. More 
than 80% of cases of coronary artery disease and more than 75% of cases of congestive 
heart failure occur in people over the age of 65 years95. 
Ageing is associated with several molecular, biophysical and biochemical changes in 
the heart96, 97. The predominant change that occurs in the cardiovascular system with 
ageing is a reduction in elasticity of the vasculature and consequent increased arterial 
stiffness98, 99. In fact, telomere length correlates negatively with pulse wave velocity100. 
It is of note that elastin degradation in the skin is related to emphysema and to arterial 
stiffness in patients with COPD76** providing a link between skin ageing, COPD and 
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atherosclerosis. In turn, telomere length has also been shown to correlate with arterial 
stiffness, which reflects ageing of the vasculature100.  
Tobacco smoke is the logic candidate to explain the accelerated ageing process that 
can be the link to the co-existence of COPD and cardiovascular disease. Interestingly, 
however, COPD patients have increased skin elastin degradation, compared with 
controls matched for age and smoking history, and this was associated with arterial 
stiffness and emphysema severity. This suggests that besides similar chronological 
age, patients with COPD experience accelerated ageing that contributes to the 
emphysema severity and arterial stiffness irrespective of the smoking history. Taken 
together, these data suggest that the destruction of the lung parenchyma, leading to 
emphysema, and the cardiovascular risk may share mechanisms related to accelerate 
ageing. 
 
Physical inactivity 
 
Physical in-activity is a known risk factor for cardiovascular disease70. The recognition 
that physical activity (PA) can prevent or delay the appearance of chronic diseases such 
as cardiovascular disease or diabetes has now a solid scientific support101, 102, 103-106. 
Inactivity is also a risk factor for the development of COPD in smokers7. An example 
that illustrates this comes from the study by Garcia-Aymerich et al 107*. In this cohort 
study, smokers who had moderate to high levels of regular PA had lower lung function 
decline over time and consequently had a lower risk of developing COPD. The benefits 
of physical activity are well known. Regular physical activity has been associated with 
an improvement in endothelial function, has anti-inflammatory effect, reduces body 
weight, fat mass and circulating lipids, the metabolic cost of activities, and improves 
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insulin sensitivity, angiogenesis and increases the resistance of myocardial cells to 
ischemia108. Exercise training constitutes the cornerstone of pulmonary and cardiac 
rehabilitation109, 110. 
 
Physical activity is markedly reduced in patients with COPD111 and is an independent 
predictor of risk of hospitalizations due to acute exacerbations and early mortality in 
COPD107*, 112. Reduced physical activity levels, a feature of COPD, constitute a risk 
factor for cardiovascular disease101 and can partially explain the higher risk of 
cardiovascular morbidity in patients with COPD. 
 
Hypoxemia and gas exchange abnormalities 
 
Patients with COPD can develop type I (hypoxemic) and type II (hypoxemic + 
hypercapnic) respiratory failure as the condition progresses. Hypoxemia, whether 
sustained in patients with severe disease or intermittent hypoxia during exercise, sleep 
or exacerbations, can influence atherogenesis by increasing systemic inflammation 
and oxidative stress, up-regulating cell-adhesion molecules, and producing 
hemodynamic stress113-115. Animal studies have shown hypoxia to be a contributor to 
atherosclerosis in the presence of dyslipidaemia, as increased lipid peroxidation, a 
marker of oxidative stress, and reduced levels of the antioxidant superoxide dismutase 
are found in the myocardial tissue of rats exposed to hypoxic environments116, 117. 
Hypoxia also induces hemodynamic stress, increasing the heart rate and cardiac 
index118, and affects the renal circulation, reducing renal blood flow and activating the 
renin-angiotensin system, resulting in increased peripheral vasoconstriction and 
oxidative stress119. Respiratory failure in patients with COPD is also associated with 
COPD as a cardiovascular disease   Rabinovich – MacNee, June 2015 
18 
 
activation of the sympathetic nervous system120, which is associated with an increased 
risk for cardiovascular disease121. 
In turn, hypoxic vasoconstriction, endothelial injury by cigarette-smoke and 
inflammation are the potential pathogenic mechanisms linked to the development of 
pulmonary arterial hypertension (PAH) in patients with COPD122. 
Respiratory acidosis resulting from hypercapnia is a well-known feature of advanced 
COPD, particularly in the advanced phase or during exacerbations. A recent study by 
Minet and colleagues has shown that respiratory acidosis could be one of the 
mechanisms resulting in endothelial dysfunction, thus adding to the burden of 
cardiovascular complications123. 
 
Polycythemia 
 
Secondary polycythemia is a known complication of COPD, and occurs mainly as a 
result of chronic hypoxemia. A prospective study by Cote and colleagues124, however, 
had shown that only 6% of 683 patients with COPD included in their study developed 
secondary polycythemia. The low incidence reported in this study may be related to 
the improvement of the management of patients with hypoxia, including the use of 
long-term oxygen therapy (LTOT). However, when present in COPD polycythemia can 
contribute to the development of pulmonary hypertension and pulmonary endothelial 
dysfunction with reduced cerebral and coronary blood flow, thus increasing the risk of 
cardiovascular events125, 126. 
 
Rather than isolated concomitant factors, the pathogenic mechanisms previously 
described can be interconnected pieces of the same puzzle linking COPD and its 
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cardiovascular comorbidities. For example cigarette smoking can constitute common 
risk factor for COPD and cardiovascular comorbidities. In turn, COPD can lead to 
cardiovascular disease through several features characteristic of the disease (e.g. 
hypoxemia, elastin degradation, systemic inflammation) (Figure 3). 
 
Interventions to treat cardiovascular comorbidities 
 
COPD associates with several comorbidities and extra-pulmonary manifestations, and 
is now considered a systemic disease with multiple organ involvement and different 
phenotypes127, 128. Cardiovascular comorbidities are significantly increased in patients 
with COPD3, 4. In turn, the presence of cardiovascular disease in these patients 
increases the risk of morbidity and mortality7, 17-20*. Therefore, to actively seek and 
treat, these comorbidities should contribute to a better management and outcomes of 
individual patients.  
 
Ischaemic Heart Disease 
Patients with COPD showed a significant increase on risk of adverse events and of 
hospital readmissions after an ischemic event129**. 
Current guidelines suggest dual antiplatelet therapy with aspirin and a P2Y12ADP 
receptor inhibitor for the treatment of IHD and should also apply to patients with COPD. 
Clopidogrel has been reported to be used more frequently in COPD and asthma130 
than in the general population. This is possibly due to a lower association with 
dyspnoea and bleeding complications reported with other P2Y12-ADP receptor 
inhibitors. 
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As mentioned previously, platelet-monocyte aggregates, increased during 
exacerbations of COPD62. Antiplatelet therapy with aspirin and clopidogrel has also 
been shown to reduce 1-year mortality in COPD131.  
 
Beta-blockers are indicated in all patients with heart failure or LV dysfunction after an 
ischemic event132. In patients with COPD undergoing vascular surgery, cardio-
selective beta-blockers reduce mortality133. Observational studies have reported the 
safe use of beta-blockers in exacerbations of COPD (ECOPD), and even a reduction 
in mortality134, 135. However, prescription of beta-blockers was significantly lower in 
individuals with airways disease136, 137. There is now additional evidence on the safety 
of beta-blockers in COPD138-140. Moreover, the benefits of selective beta-blockers 
when indicated in IHD are considerably larger than the potential associated risks. 
International guidelines for the management of COPD, such as the Global Initiative for 
COPD (GOLD)141, recommend the use of cardio-selective beta-blockers when 
indicated.  
 
The use of statins, ACE inhibitors, and angiotensin receptor blockers has also a 
positive impact on morbidity and mortality in patients with COPD and IHD142, 143. A 
recent study showed no effects of statins on exacerbations, lung function, quality of 
life or mortality144. Interestingly, patients that fulfil criteria for the use of statins were 
excluded from this study. The underuse of statins in persons with cardiac risk factors 
who have been included in retrospective studies may account in part for the 
differences between this and those studies previously reported. This highlights the 
need for early identification and treatment of cardiovascular risk in COPD patients. 
ACE inhibitors are recommended in all patients with presence of heart failure, 
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hypertension or diabetes132. Additionally, in COPD patients, ACE inhibitors may 
protect against FEV1 decline145 possibly through an anti-inflammatory effect and 
improvement of endothelial function. 
Usual COPD treatment is not contraindicated in patients with co-existing ischemic 
disease. Moreover, several lines of usual treatment for COPD may have a secondary 
benefit on reducing the risk of IHD146-148. 
Participation in cardiac rehabilitation programmes is advised for patients after an 
ischemic event132. The benefits of physical activity have been previously described in 
this review. Pulmonary rehabilitation is a key part of the management of patients with 
COPD109.  
 
Heart Failure 
Heart failure (HF) should be treated accordingly to HF guidelines as there is no 
evidence that HF should be treated differently in the presence of COPD141.  
ACE inhibitors should be used in all symptomatic patients with a left ventricular 
ejection fraction (LVEF) ≤ 40% as it improves ventricular function, patient’s well-being, 
reduces hospitalisations and increases survival149. Unlike the situation with beta-
blockers, no differences have been reported in the prescription of ACE inhibitors in 
patients with or without COPD150. Moreover, as mentioned previously the use of 
statins, ACE inhibitors, and angiotensin receptor blockers has shown, in observational 
studies, to have a positive impact on morbidity and mortality in patients with COPD 
and IHD142, 143. 
 
Beta-blockers improve survival in patients with chronic HF. The use of selective beta-
blockers has significant impact on survival in patients with HF with diagnosis of 
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COPD151 and is considered to be safe138-140. A Cochrane meta-analysis concludes that 
selective β1 beta-blockers are safe138. Similarly to the treatment of IHD, the use of 
selective beta-blockers is preferable to a non-selective beta blocker152. The NICE and 
European Society of Cardiology stated that there is no contraindication for the use of 
beta-blockers in patients with COPD149, 153. 
However, this treatment is significantly under-prescribed in these patients151 (Figure 
4). 
The use of a non-selective beta-blocker may cause a reduction on the FEV1, however 
this does not translate into deleterious effects on symptoms and quality of life154. In 
fact, some studies have shown that treatment with bisoprolol and carvedilol was well 
tolerated and produced beneficial effects on lung function in patients with heart failure 
and COPD155. Moreover, bisoprolol was superior to carvedilol on respiratory 
parameters improvement. In resume, the benefit of selective beta- blockers for the 
treatment of HF on patients with COPD overweighs any potential risk, even in severe 
COPD patients. 
 
The addition of a low-dose of an aldosterone antagonist should be considered in all 
patients with an LVEF ≤ 35% and severe symptomatic HF as it reduces hospital 
admissions and increases survival149.  
 
Angiotensin receptor blockers (ARBs) are recommended in patients with HF and an 
LVEF ≤ 40% who remain symptomatic despite optimal treatment with an ACEI and 
beta-blockers, unless also taking an aldosterone antagonist as it improves ventricular 
function and patient well-being, and reduces hospital admissions149. 
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Digoxin should be considered in patients with symptomatic HF and AF to slow a rapid 
heart rate in addition to or prior to beta-blockers149.  
 
Diuretics are recommended in patients with HF and clinical signs or symptoms of 
pulmonary congestion149. Clinicians should be aware that high doses of loop diuretics 
could produce metabolic alkalosis with subsequent induction of hypoventilation that 
could worsen hypercapnia37, 156. 
 
Warfarin is recommended in patients with HF and AF149. In elderly patients with HF 
caused by IHD, statins may be used to reduce hospitalisations149. 
 
Pulmonary hypertension 
ACCF/AHA157 and the European Society of Cardiology158 guidelines for the 
management of pulmonary hypertension recommend that in the vast majority of 
patients with COPD, in whom PH is mild, treatment should be directed to the 
underlying COPD. LTOT is indicated earlier in patients with COPD if there is evidence 
of PH. In more severe PH, specific treatment of PH in patients with COPD has not 
been adequately studied. Open label, uncontrolled observations with both Bosentan 
and sildenafil have suggested benefit, although adequately designed trials are 
lacking159-161. Worsening V/Q mismatch, resulting in further hypoxemia due to non-
selective vasodilatation is a potential risk162, 163. Likewise, the use of endothelium-
modulating agents is not recommended until data on their safety and efficacy in COPD 
are available164.  
 
Atrial Fibrillation 
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This condition should be treated according to the usual guidelines for the treatment of 
AF. The reader is referred to guidelines on the treatment of AF published elsewhere166-
168. When beta-blockers are required, selective beta-blockers are preferable over non-
selective beta-blockers141.  
 
Hypertension  
Hypertension should be treated according to usual hypertension guidelines. The 
reader is referred to guidelines on the treatment of hypertension published 
elsewhere169, 170. Again, a selective beta-blocker is preferred over a non-selective beta 
blocker141 when these drugs are required.  
 
Summary and Conclusions 
 
Cardiovascular disease is one of the most frequent associated comorbidities in 
patients with COPD and is a major contributor to morbidity and mortality. These 
comorbidities are under-recognised and, therefore, undertreated. COPD shares 
common risk factors with several cardiovascular diseases including cigarette smoking. 
In turn several features of COPD can be associated with increased cardiovascular risk, 
namely gas exchange abnormalities, polycythaemia, systemic inflammation and 
sedentary habit. Understanding the mechanisms linking COPD and cardiovascular 
disease may help to identify new targets for treatment. Cardiovascular comorbidities 
should be actively sought and treated according to usual guidelines in patients with 
COPD. Management of patients with COPD should be moving from a reductionist 
approach to an integrated approach to define, identify, and treat the multiple organ 
involvement of this complex syndrome.  
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EXPERT OPINION SECTION 
 
COPD is a multiple organ involvement syndrome. Common risk factors lead to the co-
existence of COPD and extra pulmonary comorbidities. Moreover, features of COPD 
(e.g. inactivity, gas exchange abnormalities, systemic inflammation, etc.) can also lead 
to extra-pulmonary manifestations of COPD. Both comorbidities and extra-pulmonary 
manifestations of COPD are major contributors to morbidity and mortality and are often 
under-diagnosed. There is a need for COPD management to move from a reductionist 
approach to an integrated approach that considers the disease as the multiple organ 
syndrome that COPD is. Cardiovascular diseases are of the most frequent associated 
extrapulmonary manifestations of COPD and, together with other comorbid conditions, 
should be actively sought and treated. The authors hope that the present review 
highlights the importance of cardiovascular diseases in patients with COPD and help 
to move a step forward in the management of this complex and heterogeneous 
syndrome. 
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FIVE YEARS VIEW SECTION 
There is already consensus on the heterogeneous nature and the multi-organ 
involvement of COPD, which has produced in the last decade a change in the 
paradigm in the field. There is still, however, a reductionist approach in the 
management of this condition. Evidence is continuously emerging and pointing at the 
heterogeneity of the disease where multiple phenotypes can be identified. This has 
implications for the prognosis of individual patients with COPD. The next five years 
are key to accelerate the switch towards an integrated approach in COPD 
management. This approach should incorporate an active effort to seek for, identify, 
and treat the multiple organ involvements characteristic of COPD. Cardiovascular 
disease is one of the most frequent associated comorbid conditions and contributes 
to increased morbidity and mortality. The next five years will bring new tools that will 
facilitate the management of cardiovascular comorbidities to the clinician. Biomarkers 
of cardiovascular comorbidities (e.g. circulating desmosine levels) should be made 
available to facilitate the identification of patients at risk and new therapeutic 
alternatives should emerge. The latter should improve the management of the 
common risk factors on one hand and the features of COPD that contribute to the 
development of cardiovascular disease in these patients, ultimately leading to a better 
and personalised management of the individual patients with COPD.  
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TABLE 1. Potential pathogenic mechanisms of cardiovascular 
disease in COPD 
Potential pathogenic mechanisms of 
cardiovascular disease in COPD 
Vessel wall abnormalities/Endothelial 
dysfunction  
Elastin degradation  
Systemic and lung inflammation 
Accelerated ageing 
Sedentary habit 
Gas exchange abnormalities  
Lung hyperinflation 
Polycythemia 
  
COPD as a cardiovascular disease   Rabinovich – MacNee, June 2015 
40 
 
Figure 1. COPD is associated with subclinical atherosclerosis 
 
 
 
 
 
 
 
 
 
Reproduced with permission12 
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Figure 2. Heart disease is associated with increased mortality in the 
ECLIPSE cohort. 
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Figure 3. Interaction of the pathogenic mechanisms of 
cardiovascular disease in COPD 
 
 
 
 
 
  
 
Systemic Inflammation
TNF, IL-6, IL-8, IL-1β, CRP
serum amiloid A, ferritin, fibrinogen
Lung Inflammation
Cardiovascular Disease
Shared Risk Factors
• Environmental factors
Cigarette smoking, aging, 
poor general health condition
• Genetic factors
Physical Inactivity
Endothelial dysfunction
Accelerated ageing
Gas exchange abnormalities
Lung hyperinflation
Polycythemia
Elastin
degradation
Elastin
degradation
COPD as a cardiovascular disease   Rabinovich – MacNee, June 2015 
43 
 
Figure 4. Trends in beta-blockers prescribing in patients with HF, 
comparing those with and without COPD. 
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